X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (40) 40
female (35) 35
oncology (35) 35
middle aged (28) 28
adult (26) 26
breast cancer (22) 22
aged (19) 19
cancer (17) 17
breast neoplasms - drug therapy (13) 13
antineoplastic combined chemotherapy protocols - therapeutic use (12) 12
treatment outcome (11) 11
breast neoplasms - pathology (10) 10
chemotherapy (10) 10
follow-up studies (10) 10
male (10) 10
aged, 80 and over (9) 9
metastasis (9) 9
index medicus (8) 8
survival analysis (8) 8
therapy (8) 8
drug administration schedule (7) 7
medical research (7) 7
medicine, general & internal (7) 7
breast (6) 6
breast neoplasms (6) 6
cancer therapies (6) 6
cyclophosphamide (6) 6
medical oncology (6) 6
metastases (6) 6
patients (6) 6
time factors (6) 6
antineoplastic combined chemotherapy protocols - administration & dosage (5) 5
bone marrow (5) 5
breast neoplasms - genetics (5) 5
breast neoplasms - mortality (5) 5
breast neoplasms - surgery (5) 5
further section (5) 5
health aspects (5) 5
prognosis (5) 5
receptors, calcitriol - genetics (5) 5
research (5) 5
trastuzumab (5) 5
women (5) 5
breast neoplasms - metabolism (4) 4
care and treatment (4) 4
chemotherapy, adjuvant (4) 4
clinical trials (4) 4
combined modality therapy (4) 4
disease-free survival (4) 4
diseases (4) 4
double-blind method (4) 4
doxorubicin - administration & dosage (4) 4
neoadjuvant therapy (4) 4
prostate-cancer (4) 4
quality of life (4) 4
risk (4) 4
risk factors (4) 4
taxoids - administration & dosage (4) 4
treatment (4) 4
tumor (4) 4
adjuvant treatment (3) 3
alpha (3) 3
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
bone cancer (3) 3
bone marrow transplantation (3) 3
bone metastases (3) 3
bone neoplasms - secondary (3) 3
breast cancertreatment (3) 3
breast neoplasms therapy (3) 3
brustkrebs (3) 3
calcitriol - pharmacology (3) 3
cell line, tumor (3) 3
cells (3) 3
cyclophosphamide - administration & dosage (3) 3
dose-response relationship, drug (3) 3
electronic book (3) 3
electronic books (3) 3
erbb-2 protein (3) 3
fluoride (3) 3
fluorides (3) 3
follow-up (3) 3
health & fitness (3) 3
health & fitness diseasescancer (3) 3
kaplan-meier estimate (3) 3
medical (3) 3
neoadjuvant chemotherapy (3) 3
neoplasm invasiveness (3) 3
neoplasm staging (3) 3
obstetrics & gynecology (3) 3
odds ratio (3) 3
oncology, experimental (3) 3
paclitaxel (3) 3
polymorphism, genetic (3) 3
predictive value of tests (3) 3
product development (3) 3
prognostic-significance (3) 3
proportional hazards models (3) 3
radiology, nuclear medicine & medical imaging (3) 3
receptor (3) 3
receptor, erbb-2 - metabolism (3) 3
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 3, pp. 367 - 377
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2006, Volume 355, Issue 18, pp. 1851 - 1862
Journal Article
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
Journal Article
Journal of Nuclear Medicine, ISSN 0161-5505, 03/2019, Volume 60, Issue 3, pp. 322 - 327
Our purpose was to establish whether noninvasive measurement of changes in 18F-fluoride metabolic flux to bone mineral (Ki) by PET/CT can provide incremental... 
Medical services | Positron emission | Fluorine isotopes | Breast cancer | Metastasis | Injection | Fluorides | Metabolism | Patients | Metastases | Metabolic flux | Bone cancer | Fluoride | Computed tomography | Mathematical analysis | Tomography | Breast | Bone | Lesions | Cancer | Clinical | bone metastases | breast cancer | heterogeneity, 18F-fluoride PET
Journal Article
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 05/2005, Volume 11, Issue 9, pp. 3579 - 3586
Journal Article
by Earl, Helena and Earl, Helena M and Hiller, Louise and Vallier, Anne-Laure and Loi, Shrushma and McAdam, Karen and Hughes-Davies, Luke and Harnett, Adrian N and Ah-See, Mei-Lin and Simcock, Richard and Rea, Daniel and Raj, Sanjay and Woodings, Pamela and Harries, Mark and Howe, Donna and Raynes, Kerry and Higgins, Helen B and Wilcox, Maggie and Plummer, Chris and Mansi, Janine and Gounaris, Ioannis and Mahler–Araujo, Betania and Provenzano, Elena and Chhabra, Anita and Abraham, Jean E and Caldas, Carlos and Hall, Peter S and McCabe, Christopher and Hulme, Claire and Miles, David and Wardley, Andrew M and Cameron, David A and Dunn, Janet A and Agarwal, Roshan and Algurafi, Hafiz and Allerton, Rozenn and Archer, Caroline and Armstrong, Anne and Bale, Catherine and Barraclough, Lisa and Barthakur, Urmila and Bedi, Carolyn and Benstead, Kim and Bloomfield, David and Bowen, Rebecca and Bradley, Chris and Brown, Jane and Butt, Mohammad and Churn, Mark and Cleator, Susan and Cliff, Joanne and Crellin, Perric and Daly, Margaret and De Silva-Minor, Shiroma and Dhadda, Amandeep and Din, Omar and Down, Sue and Eaton, David and Eichholz, Andrew and Epurescu, Daniel and Goh, Chee and Goodman, Andrew and Grieve, Robert and Hadaki, Maher and Harper-Wynne, Catherine and Hayward, Larry and Humphreys, Alison and Innes, Helen and Jafri, Mariam and Jegannathen, Apurna and Kelleher, Muireann and Kristeleit, Hartmut and Lee, Daniela and Lupton, Susan and MacGregor, Carol and Malik, Zafar and Marshall, Jennifer and McGolick, Trevor and Mehra, Rakesh and Mithal, Natasha and Moss, Charlotte and Moss, Aian and Mukesh, Mukesh and Neal, Anthony and Nelmes, Daniel and Neville-Webbe, Helen and Newby, Jacqueline and O'Reilly, Susan and Ostler, Peter and Persic, Mojca and Pettit, Laura and Raja, Fharat and Reed, Catherine and Rigg, Anne and Roe, Helen and Shah, Nihal and Simmonds, Peter and Sims, Eliot and Smith, Sarah and Storey, Nicola and ... and PERSEPHONE Steering Comm & Trial and PERSEPHONE Steering Committee and Trial Investigators
The Lancet, ISSN 0140-6736, 06/2019, Volume 393, Issue 10191, pp. 2599 - 2612
Adjuvant trastuzumab significantly improves outcomes for patients with HER2-positive early breast cancer. The standard treatment duration is 12 months but... 
MEDICINE, GENERAL & INTERNAL | MULTICENTER | THERAPY | HERCEPTIN | RECOMMENDATIONS | CARDIAC EVENTS | FOLLOW-UP | OPEN-LABEL | CHEMOTHERAPY | NEOADJUVANT PERTUZUMAB | PLUS | Breast cancer | Medical research | Toxicity | Research & development--R&D | Medical treatment | Cancer therapies | Survival | ErbB-2 protein | Chemotherapy | Hypotheses | Randomization | Motivation | Technology assessment | Breast | Trastuzumab
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 05/2018, Volume 36, Issue 15_suppl, pp. e13055 - e13055
Journal Article